ANT308 TFA serves as an antagonist for the vasoactive intestinal peptide (VIP receptor). It significantly enhances the activation and proliferation of T cells. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 TFA impedes the migration and metastasis of melanoma cells and induces apoptosis. This compound is applicable in research related to acute myeloid leukemia (AML) and uveal melanoma (UVM).

ANT308 (0.1-10 μM, 72 h) TFA demonstrates a concentration-dependent reduction in cell viability of B16F10 and HT-144 cells. At 0 μM for 72 hours, it reduces the proportion of cells in S phase and induces apoptosis in B16LS9 and Mel 290 cells. Furthermore, ANT308 (10 μM, 72 h) TFA significantly inhibits cell migration in B16LS9, Mel 290, and HT-144 cell lines. It also decreases the expression of MCAM and N-cadherin by inhibiting VIP-VPAC2 signaling over a 72-hour period.

ANT308 (100 μg/100 μL PBS, subcutaneous injection, administered twice daily for 10 days) TFA has been shown to decrease both the number and size of hepatic metastases following intraocular or subcutaneous melanoma injections in mice. Additionally, it exhibits a tendency to reduce the tumor volume at the primary tumor site.